Lorenzo Pilla - Concepedia

Author

Lorenzo Pilla

Fondazione IRCCS Istituto Nazionale dei Tumori

Also Known As

Erica Bertocci, L. Pilla, Lorenzo Pilla

Publications

Citations

H-Index

Concepts

All Affiliations

Fondazione IRCCS Istituto Nazionale dei Tumori University of Siena Istituti di Ricovero e Cura a Carattere Scientifico San Raffaele University of Rome Tumori Foundation

About

Lorenzo Pilla is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	1K
2	Cell Biology	2	2	130
3	Engineering	1	1	27
4	Health Sciences	1	1	10
5	Allergy	1	1	20

Lorenzo Pilla

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine Paola Filipazzi, Roberta Valenti, Veronica Huber, Journal of Clinical Oncology	2007	639
Human Tumor-Released Microvesicles Promote the Differentiation of Myeloid Cells with Transforming Growth Factor-β–Mediated Suppressive Activity on T Lymphocytes Roberta Valenti, Veronica Huber, Paola Filipazzi, Cancer Research	2006	479
Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings Filiberto Belli, Alessandro Testori, Licia Rivoltini, Journal of Clinical Oncology	2002	385
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial Anna Maria Di Giacomo, Paolo A. Ascierto, Lorenzo Pilla, The Lancet Oncology OncologySingle-arm Phase 2MelanomaImmune Checkpoint InhibitorPharmacotherapy	2012	280
IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells Cristina Tecchio, Veronica Huber, Patrizia Scapini, Blood	2004	158
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study Anna Maria Di Giacomo, Paolo A. Ascierto, Paola Queirolo, Annals of Oncology OncologyItalian NetworkMedicineMelanomaClinical Trials	2014	139
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients Lorenzo Pilla, Roberto Patuzzo, Licia Rivoltini, Cancer Immunology Immunotherapy Tumor ImmunologyCancer ImmunosurveillancePhase Ii TrialMedicineMelanoma	2005	137
Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells Licia Rivoltini, Chiara Castelli, Matteo Giovanni Carrabba, The Journal of Immunology	2003	120
Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-α Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors Tiziana Di Pucchio, Lorenzo Pilla, Imerio Capone, Cancer Research	2006	115
Role of Cross-Talk between IFN-α-Induced Monocyte-Derived Dendritic Cells and NK Cells in Priming CD8+ T Cell Responses against Human Tumor Antigens Diégo Tosi, Roberta Valenti, Agata Cova, The Journal of Immunology Adaptive Immune SystemImmunologyImmune RegulationImmunodominanceImmunologic Mechanism	2004	92

Page 1